Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) announced its earnings results on Monday. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($2.05) by $1.74, FiscalAI reports.
Alaunos Therapeutics Stock Performance
Alaunos Therapeutics stock opened at $1.60 on Tuesday. Alaunos Therapeutics has a twelve month low of $0.72 and a twelve month high of $4.50. The firm has a market cap of $5.30 million, a PE ratio of -0.84 and a beta of -1.02. The firm’s 50 day moving average price is $1.64 and its two-hundred day moving average price is $2.27.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Alaunos Therapeutics in a report on Friday. TD Cowen assumed coverage on shares of Alaunos Therapeutics in a research note on Friday. They issued a “buy” rating for the company. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Alaunos Therapeutics has an average rating of “Hold”.
Get Our Latest Analysis on Alaunos Therapeutics
Alaunos Therapeutics Company Profile
Alaunos Therapeutics was a biotechnology company focused on developing engineered T-cell therapies for cancer. Its research centered on T-cell receptor (TCR) therapies designed to help a patient’s immune cells recognize and attack tumors. The company’s main program investigated genetically modified T cells targeting cancer-associated mutations, including mutations in the KRAS gene, in patients with solid tumors. Its approach used a library of TCRs intended to recognize different tumor mutations.
Read More
- Five stocks we like better than Alaunos Therapeutics
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
